Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 190

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1B
Chunk 190
---
 with respect to the Company’s restricted stock units during the year ended December 31, 2024 is as follows:SharesWeighted AverageGrant Date Fair ValueNonvested shares at December 31, 202332,558 $4.30 Granted308,700 1.92 Vested/Issued(32,558)4.30 Forfeited(52,210)1.92 Nonvested shares at December 31, 2024256,490 $1.92 As of December 31, 2024, there was $0.4 million of unrecognized compensation cost related to restricted stock units, which is expected to be recognized over a weighted average period of 3.2 years.Compensation Expense SummaryThe Company recognized the following compensation cost related to employee and non-employee share-based compensation activity for the periods presented (in thousands): Year Ended December 31,20242023Selling, general and administrative$6,782 $7,450 Research and development4,057 4,504 Total$10,839 $11,954 The Company uses the Black-Scholes option pricing model to determine the estimated fair value for share-based option awards. Option pricing and models require the input of various assumptions, including the option’s expected life, expected dividend yield, price volatility and risk-free interest rate of the underlying stock. Forfeitures are recognized and accounted for as they occur.The calculation was based on the following assumptions: Year Ended December 31,20242023Weighted average grant date fair value (per share)$1.41$6.83Risk-free interest rate4.13% - 4.47%3.42% - 4.67%Expected volatility88.29% - 91.46%89.94% - 101.49%Expected term (in years)5.0 - 6.15.2 - 6.1Expected dividend yield——The Company determines the assumptions used in the option pricing model in the following manner:Risk-Free Interest Rate – For the determination of the risk-free interest rates, the Company utilizes the U.S. Treasury yield curve for instruments in effect at the time of measurement with a term commensurate with the expected term assumption.Expected Volatility – The Company based its estimate of expected volatility on a weighted average using the Company's limited historical stock price volatility data, supplemented with the estimated and expected volatilities of a guideline group of publicly traded companies.